Science Daily : Hormone Disorders
Hormone Disorders News -- ScienceDaily
Read the latest research on endocrinology. Learn about hormone disorders, new hormone treatment options, hormone therapy and more.

Hormone Disorders News -- ScienceDaily
  • Cushing's syndrome: Researchers characterize new tumor syndrome
    Mutations in a gene known as “ARMC5” promote the growth of benign tumors in the adrenal glands and on the meninges, researchers report. ARMC5 appears to belong to the group of so-called tumor suppressor genes. It is the first time in years that scientists have characterized such a gene.

  • Hormone loss could be involved in colon cancer
    Like diabetes, colon cancer may be caused in part by the loss of one hormone, suggesting hormone replacement therapy could stall cancer formation. New evidence suggests that human colon cells may become cancerous when they lose the ability to produce a hormone that helps the cells maintain normal biology. If verified by further studies, it suggests that treating patients at high risk for colon cancer by replacing the hormone guanylin could prevent the development of cancer.

  • Endocrine-disrupting chemicals alter thyroid hormone activity during pregnancy, affect thyroid hormone activity
    A new study in human placenta provides the strongest evidence to date that Endocrine Disrupting Chemicals (EDCs) can interfere with thyroid hormone action in pregnant women. The implication is that flame retardant chemicals called polychlorinated biphenyls (PCBs) can infiltrate the placenta during pregnancy and affect thyroid hormone activity at the cellular level, according to a new study.

  • Experts recommend against diagnosing testosterone deficiency in women
    A Clinical Practice Guideline (CPG) advising against the use of testosterone therapy in healthy women has been published. "Currently, there isn't enough evidence that any benefits outweigh the risks to most women," an expert said. "More research is needed to determine the long-term safety of testosterone therapy in postmenopausal women."

  • New guidelines for treatment of hypothyroidism endorse current therapy
    Levothyroxine is considered the gold standard therapy for an underactive thyroid gland, and a new review of therapies for the condition -- including combining levothyroxine with another agent -- has not altered that assessment, say a team of investigators. Their analysis finds insufficient consistent data exist to recommend a change in use of levothyroxine -- whether generic, or sold under various trade names, such as Synthroid -- as the only drug needed to treat hypothyroidism.

The Canary Club is an educational advisory group with a team of medical advisors headed by Richard Shames, M.D.